0
2022
Biosimilars Market

Biosimilars Market

by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A00573
Jun 2022 | Pages: 242
Tables: 124
Charts: 59
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Biosimilars Market Research, 2031

The global biosimilars market was valued at $15.9 billion in 2021, and is projected to reach $143.6 billion by 2031, growing at a CAGR of 24.7% from 2022 to 2031. Biosimilar drugs, are biotherapeutic products similar in terms of quality, safety, and efficacy to an already licensed reference biotherapeutic product. Biologics are used for treatment of chronic diseases such as cancer and autoimmune diseases. Development of biologics is a costly and timeconsuming process while biosimilar development saves time and resources by avoiding unnecessary duplication of clinical trials.

The COVID-19 outbreak is anticipated to have a negative impact on growth of the biosimilars market, owing to implementation of lockdowns in many countries. The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development. The entire healthcare industry has focused on life saving products during the pandemic. In addition, there is delay in product approvals and product launches, owing to pandemic situations, which further restricts expansion of the biosimilar market. Furthermore, most clinical trials are postponed to avoid spread of infections, which slows down the drug development process. Thus, COVID-19 had a significant negative impact on the biosimilars market. The healthcare sector has been restructured to provide safer healthcare facilities. Hence, the market is anticipated to grow in the post pandemic situations.

Biosimilars Market, insulin biosimilars market, Biosimilars Market Size, Biosimilars Market Share, Biosimilars Market Analysis, Biosimilars Market Growth, Biosimilars Market Opportunity, Biosimilars Market Trends, Biosimilars Market Forecast

Growth of the global biosimilars market is majorly driven by increase in prevalence of different types of cancers such as lung cancer, blood cancer, and brain tumor. For instance, as per the Globocan 2020, lung cancer is the second ranked cancer, in terms of patient count in Europe with estimated 477,534 newly diagnosed patients. Biosimilars have major role in treatment of cancer as supportive treatment for chemotherapy. For instance, Novartis, a leading pharmaceutical company, offers a biosimilar Ziextenzo (Pegfilgrastim-bmez Injection), used to reduce the chance of infection in people who have certain types of cancers and receive chemotherapy medications that may decrease number of neutrophils.  Hence,Increase in prevalence of various cancers boost growth of the global biosimilars market size.

Increase in prevalence of autoimmune diseases such as ankylosing spondylitis, and rheumatoid arthritis drives growth of the Biosimilars Market Size. For instance, according to a paperpublished in “Scandinavian Journal of Rheumatology”, in 2020, titled ‘Prevalence of ankylosing spondylitis in Spain’, about 7.3% population showed positive screening for ankylosing spondylitis. Biosimilars, such as infliximab-axxq (Avsola), infliximab-qbtx (Ixifi), infliximab-dyyb (Inflectra), and infliximab-abda (Renflexis) are used for treatment of chronic pain in arthritis. Furthermore, increase in number of orthopedic hospitals and diagnostic centers boost diagnosis and treatment rate of diseases. For instance, according to Definitive Healthcare data in 2020, there were more than 30,500 orthopedic surgeons practicing in the U.S. Thus, increase in prevalence of painful autoimmune diseases and rise in number of hospitals contribute toward Biosimilars Market Growth.

Increase in incidences of diabetes boosts growth of the insulin biosimilars market. For instance, according to the International Diabetes Federation (IDF), in 2020, approximately 537 million adults (20-79 years) were living with diabetes and this number is expected to rise from 643 million in 2030 to 783 million in 2045. The biosimilar of insulin analogues serves as cost-effective option for diabetes patients. For instance, Biocon biologics, a leading biosimilar company, received U.S. food and drug administration (FDA) approval for first interchangeable biosimilar Semglee (insulin glargine-yfgn) injection for treatment of diabetes. Thus, rise in prevalence of diabetes and latest product approvals drive growth of the Biosimilars Market Size.

Biosimilars Market Opportunity created by increase in product approvals and emerging interest in biosimilars by key players . For instance, in December 2021, Coherus BioSciences, a leading biosimilar developer, received U.S. food and drug administration (FDA) approval for adalimumab biosimilar and Yusimry (CHS-1420) for the treatment of tumor. Thus ,increase in product approvals by respective authorities boosts growth of the Biosimilars Industry.

Moreover, favorable government policies and new product launches in the global Biosimilars Industry along with regulatory approvals are expected to contribute toward growth of  themarket. For instance, in 2021, the U.S. President Joe Biden signed Advancing Education on Biosimilars Act of 2021, which authorizes the food and drug administration (FDA) to educate patients and healthcare providers about benefits of biosimilars. This follows reintroduction of Bolstering Innovative Option to Save Immediately on Medicines Act  (BIOSIM Act), which increases reimbursement of biosimilar drugs. However, complex manufacturing and higher cost of biosimilar development hamper growth of the market.

The biosimilars market is segmented on the basis of type, application, and region. By type, the market is categorized into human growth hormone, erythropoietin, monoclonal antibodies, insulin, granulocyte-colony stimulating factor, and others.

Depending on application, it is divided into blood disorders, oncology diseases, chronic & autoimmune diseases, and others.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).

The biosimilars market is segmented into Application and Type.

Biosimilars Market
By Type

Your browser does not support the canvas element.

Monoclonal antibodies segment holds a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Depending on type, the monoclonal antibodies segment is expected to dominate the Biosimilars Market Share in 2021, and is expected to continue during the Biosimilars Market Forecast period, owing to increase in R&D activities to develop new biosimilars and rise in use of monoclonal antibodies for cancer treatment. However, the insulin segment is expected to witness considerable growth during the forecast period,  owingto increase in prevalence of diabetes.

Biosimilars Market
By Application

Your browser does not support the canvas element.

Oncology diseases segment holds a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By application, the oncology diseases segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to increase in prevalence of cancer. However, the chronic & autoimmune diseases segment is expected to witness considerable growth during the forecast period, owing to rise in product approvals and increase in demand for advanced treatment.

Biosimilars Market
By Region

2031
Europe 
Asia-Pacific
North America
LAMEA

Europe region holds a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Depending on the region, Europe garnered a major share in the biosimilars market in 2021, and is expected to dominate the global market during the forecast period, owing to rise in prevalence of cancer, favorable government initiatives, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register significant growth, owing to increase in number of hospitals, prevalence of cancer, and high population.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimilars market analysis from 2021 to 2031 to identify the prevailing biosimilars market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the biosimilars market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global biosimilars market trends, key players, market segments, application areas, and market growth strategies.

Biosimilars Market Report Highlights

Aspects Details
By Application
  • Blood disorders
  • Oncology diseases
  • Chronic and autoimmune diseases
  • Others
By Type
  • Human growth hormone
  • Erythropoietin
  • Monoclonal antibodies
  • Insulin
  • Granulocyte-Colony Stimulating Factor
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Teva Pharmaceutical Industries Limited, Kashiv Bio Sciences, reliance life sciences, Intas Pharmaceutical Ltd, Amgen Inc., Pfizer Inc., Dr. Reddy’s Laboratories, Merck & Co. Inc., Biocon Ltd, Eli Lilly and Company
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: BIOSIMILARS MARKET, BY TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Human growth hormone

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Erythropoietin

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Monoclonal antibodies

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 Insulin

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

    • 4.6 Granulocyte-Colony Stimulating Factor

      • 4.6.1 Key market trends, growth factors and opportunities

      • 4.6.2 Market size and forecast, by region

      • 4.6.3 Market analysis by country

    • 4.7 Others

      • 4.7.1 Key market trends, growth factors and opportunities

      • 4.7.2 Market size and forecast, by region

      • 4.7.3 Market analysis by country

  • CHAPTER 5: BIOSIMILARS MARKET, BY APPLICATION

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Blood disorders

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Oncology diseases

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Chronic and autoimmune diseases

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

    • 5.5 Others

      • 5.5.1 Key market trends, growth factors and opportunities

      • 5.5.2 Market size and forecast, by region

      • 5.5.3 Market analysis by country

  • CHAPTER 6: BIOSIMILARS MARKET, BY REGION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 North America

      • 6.2.1 Key trends and opportunities

      • 6.2.2 North America Market size and forecast, by Type

      • 6.2.3 North America Market size and forecast, by Application

      • 6.2.4 North America Market size and forecast, by country

        • 6.2.4.1 U.S.
          • 6.2.4.1.1 Market size and forecast, by Type
          • 6.2.4.1.2 Market size and forecast, by Application
        • 6.2.4.2 Canada
          • 6.2.4.2.1 Market size and forecast, by Type
          • 6.2.4.2.2 Market size and forecast, by Application
        • 6.2.4.3 Mexico
          • 6.2.4.3.1 Market size and forecast, by Type
          • 6.2.4.3.2 Market size and forecast, by Application
    • 6.3 Europe

      • 6.3.1 Key trends and opportunities

      • 6.3.2 Europe Market size and forecast, by Type

      • 6.3.3 Europe Market size and forecast, by Application

      • 6.3.4 Europe Market size and forecast, by country

        • 6.3.4.1 Germany
          • 6.3.4.1.1 Market size and forecast, by Type
          • 6.3.4.1.2 Market size and forecast, by Application
        • 6.3.4.2 France
          • 6.3.4.2.1 Market size and forecast, by Type
          • 6.3.4.2.2 Market size and forecast, by Application
        • 6.3.4.3 U.K.
          • 6.3.4.3.1 Market size and forecast, by Type
          • 6.3.4.3.2 Market size and forecast, by Application
        • 6.3.4.4 Italy
          • 6.3.4.4.1 Market size and forecast, by Type
          • 6.3.4.4.2 Market size and forecast, by Application
        • 6.3.4.5 Spain
          • 6.3.4.5.1 Market size and forecast, by Type
          • 6.3.4.5.2 Market size and forecast, by Application
        • 6.3.4.6 Rest of Europe
          • 6.3.4.6.1 Market size and forecast, by Type
          • 6.3.4.6.2 Market size and forecast, by Application
    • 6.4 Asia-Pacific

      • 6.4.1 Key trends and opportunities

      • 6.4.2 Asia-Pacific Market size and forecast, by Type

      • 6.4.3 Asia-Pacific Market size and forecast, by Application

      • 6.4.4 Asia-Pacific Market size and forecast, by country

        • 6.4.4.1 Japan
          • 6.4.4.1.1 Market size and forecast, by Type
          • 6.4.4.1.2 Market size and forecast, by Application
        • 6.4.4.2 China
          • 6.4.4.2.1 Market size and forecast, by Type
          • 6.4.4.2.2 Market size and forecast, by Application
        • 6.4.4.3 Australia
          • 6.4.4.3.1 Market size and forecast, by Type
          • 6.4.4.3.2 Market size and forecast, by Application
        • 6.4.4.4 India
          • 6.4.4.4.1 Market size and forecast, by Type
          • 6.4.4.4.2 Market size and forecast, by Application
        • 6.4.4.5 South Korea
          • 6.4.4.5.1 Market size and forecast, by Type
          • 6.4.4.5.2 Market size and forecast, by Application
        • 6.4.4.6 Rest of Asia-Pacific
          • 6.4.4.6.1 Market size and forecast, by Type
          • 6.4.4.6.2 Market size and forecast, by Application
    • 6.5 LAMEA

      • 6.5.1 Key trends and opportunities

      • 6.5.2 LAMEA Market size and forecast, by Type

      • 6.5.3 LAMEA Market size and forecast, by Application

      • 6.5.4 LAMEA Market size and forecast, by country

        • 6.5.4.1 Brazil
          • 6.5.4.1.1 Market size and forecast, by Type
          • 6.5.4.1.2 Market size and forecast, by Application
        • 6.5.4.2 Saudi Arabia
          • 6.5.4.2.1 Market size and forecast, by Type
          • 6.5.4.2.2 Market size and forecast, by Application
        • 6.5.4.3 South Africa
          • 6.5.4.3.1 Market size and forecast, by Type
          • 6.5.4.3.2 Market size and forecast, by Application
        • 6.5.4.4 Rest of LAMEA
          • 6.5.4.4.1 Market size and forecast, by Type
          • 6.5.4.4.2 Market size and forecast, by Application
  • CHAPTER 7: COMPANY LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top winning strategies

    • 7.3. Product Mapping of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Key developments

  • CHAPTER 8: COMPANY PROFILES

    • 8.1 Amgen Inc.

      • 8.1.1 Company overview

      • 8.1.2 Company snapshot

      • 8.1.3 Operating business segments

      • 8.1.4 Product portfolio

      • 8.1.5 Business performance

      • 8.1.6 Key strategic moves and developments

    • 8.2 Biocon Ltd

      • 8.2.1 Company overview

      • 8.2.2 Company snapshot

      • 8.2.3 Operating business segments

      • 8.2.4 Product portfolio

      • 8.2.5 Business performance

      • 8.2.6 Key strategic moves and developments

    • 8.3 Dr. Reddy’s Laboratories

      • 8.3.1 Company overview

      • 8.3.2 Company snapshot

      • 8.3.3 Operating business segments

      • 8.3.4 Product portfolio

      • 8.3.5 Business performance

      • 8.3.6 Key strategic moves and developments

    • 8.4 Eli Lilly and Company

      • 8.4.1 Company overview

      • 8.4.2 Company snapshot

      • 8.4.3 Operating business segments

      • 8.4.4 Product portfolio

      • 8.4.5 Business performance

      • 8.4.6 Key strategic moves and developments

    • 8.5 Intas Pharmaceutical Ltd

      • 8.5.1 Company overview

      • 8.5.2 Company snapshot

      • 8.5.3 Operating business segments

      • 8.5.4 Product portfolio

      • 8.5.5 Business performance

      • 8.5.6 Key strategic moves and developments

    • 8.6 Kashiv Bio Sciences

      • 8.6.1 Company overview

      • 8.6.2 Company snapshot

      • 8.6.3 Operating business segments

      • 8.6.4 Product portfolio

      • 8.6.5 Business performance

      • 8.6.6 Key strategic moves and developments

    • 8.7 Merck & Co. Inc.

      • 8.7.1 Company overview

      • 8.7.2 Company snapshot

      • 8.7.3 Operating business segments

      • 8.7.4 Product portfolio

      • 8.7.5 Business performance

      • 8.7.6 Key strategic moves and developments

    • 8.8 Pfizer Inc.

      • 8.8.1 Company overview

      • 8.8.2 Company snapshot

      • 8.8.3 Operating business segments

      • 8.8.4 Product portfolio

      • 8.8.5 Business performance

      • 8.8.6 Key strategic moves and developments

    • 8.9 reliance life sciences

      • 8.9.1 Company overview

      • 8.9.2 Company snapshot

      • 8.9.3 Operating business segments

      • 8.9.4 Product portfolio

      • 8.9.5 Business performance

      • 8.9.6 Key strategic moves and developments

    • 8.10 Teva Pharmaceutical Industries Limited

      • 8.10.1 Company overview

      • 8.10.2 Company snapshot

      • 8.10.3 Operating business segments

      • 8.10.4 Product portfolio

      • 8.10.5 Business performance

      • 8.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 2. BIOSIMILARS MARKET REVENUE, FOR HUMAN GROWTH HORMONE, BY REGION , 2021-2031,($MILLION)
    TABLE 3. BIOSIMILARS MARKET FOR HUMAN GROWTH HORMONE BY COUNTRY, 2021-2031,($MILLION)
    TABLE 4. BIOSIMILARS MARKET REVENUE, FOR ERYTHROPOIETIN, BY REGION , 2021-2031,($MILLION)
    TABLE 5. BIOSIMILARS MARKET FOR ERYTHROPOIETIN BY COUNTRY, 2021-2031,($MILLION)
    TABLE 6. BIOSIMILARS MARKET REVENUE, FOR MONOCLONAL ANTIBODIES, BY REGION , 2021-2031,($MILLION)
    TABLE 7. BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES BY COUNTRY, 2021-2031,($MILLION)
    TABLE 8. BIOSIMILARS MARKET REVENUE, FOR INSULIN, BY REGION , 2021-2031,($MILLION)
    TABLE 9. BIOSIMILARS MARKET FOR INSULIN BY COUNTRY, 2021-2031,($MILLION)
    TABLE 10. BIOSIMILARS MARKET REVENUE, FOR GRANULOCYTE-COLONY STIMULATING FACTOR, BY REGION , 2021-2031,($MILLION)
    TABLE 11. BIOSIMILARS MARKET FOR GRANULOCYTE-COLONY STIMULATING FACTOR BY COUNTRY, 2021-2031,($MILLION)
    TABLE 12. BIOSIMILARS MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
    TABLE 13. BIOSIMILARS MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
    TABLE 14. GLOBAL BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 15. BIOSIMILARS MARKET REVENUE, FOR BLOOD DISORDERS, BY REGION , 2021-2031,($MILLION)
    TABLE 16. BIOSIMILARS MARKET FOR BLOOD DISORDERS BY COUNTRY, 2021-2031,($MILLION)
    TABLE 17. BIOSIMILARS MARKET REVENUE, FOR ONCOLOGY DISEASES, BY REGION , 2021-2031,($MILLION)
    TABLE 18. BIOSIMILARS MARKET FOR ONCOLOGY DISEASES BY COUNTRY, 2021-2031,($MILLION)
    TABLE 19. BIOSIMILARS MARKET REVENUE, FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION , 2021-2031,($MILLION)
    TABLE 20. BIOSIMILARS MARKET FOR CHRONIC AND AUTOIMMUNE DISEASES BY COUNTRY, 2021-2031,($MILLION)
    TABLE 21. BIOSIMILARS MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
    TABLE 22. BIOSIMILARS MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
    TABLE 23. BIOSIMILARS MARKET, BY REGION, 2021-2031,($MILLION)
    TABLE 24. NORTH AMERICA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 25. NORTH AMERICA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 26. NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 27. U.S. BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 28. U.S. BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 29. CANADA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 30. CANADA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 31. MEXICO BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 32. MEXICO BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 33. EUROPE BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 34. EUROPE BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 35. EUROPE BIOSIMILARS MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 36. GERMANY BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 37. GERMANY BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 38. FRANCE BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 39. FRANCE BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 40. U.K. BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 41. U.K. BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 42. ITALY BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 43. ITALY BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 44. SPAIN BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 45. SPAIN BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 46. REST OF EUROPE BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 47. REST OF EUROPE BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 48. ASIA-PACIFIC BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 49. ASIA-PACIFIC BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 50. ASIA-PACIFIC BIOSIMILARS MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 51. JAPAN BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 52. JAPAN BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 53. CHINA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 54. CHINA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 55. AUSTRALIA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 56. AUSTRALIA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 57. INDIA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 58. INDIA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 59. SOUTH KOREA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 60. SOUTH KOREA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 61. REST OF ASIA-PACIFIC BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 62. REST OF ASIA-PACIFIC BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 63. LAMEA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 64. LAMEA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 65. LAMEA BIOSIMILARS MARKET, BY COUNTRY, 2021-2031,($MILLION)
    TABLE 66. BRAZIL BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 67. BRAZIL BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 68. SAUDI ARABIA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 69. SAUDI ARABIA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 70. SOUTH AFRICA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 71. SOUTH AFRICA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 72. REST OF LAMEA BIOSIMILARS MARKET, BY TYPE, 2021-2031,($MILLION)
    TABLE 73. REST OF LAMEA BIOSIMILARS MARKET, BY APPLICATION, 2021-2031,($MILLION)
    TABLE 74.AMGEN INC.: COMPANY SNAPSHOT
    TABLE 75.AMGEN INC.: OPERATING SEGMENTS
    TABLE 76.AMGEN INC.: PRODUCT PORTFOLIO
    TABLE 77.AMGEN INC.: NET SALES,
    TABLE 78.AMGEN INC.: KEY STRATERGIES
    TABLE 79.BIOCON LTD: COMPANY SNAPSHOT
    TABLE 80.BIOCON LTD: OPERATING SEGMENTS
    TABLE 81.BIOCON LTD: PRODUCT PORTFOLIO
    TABLE 82.BIOCON LTD: NET SALES,
    TABLE 83.BIOCON LTD: KEY STRATERGIES
    TABLE 84.DR. REDDY’S LABORATORIES: COMPANY SNAPSHOT
    TABLE 85.DR. REDDY’S LABORATORIES: OPERATING SEGMENTS
    TABLE 86.DR. REDDY’S LABORATORIES: PRODUCT PORTFOLIO
    TABLE 87.DR. REDDY’S LABORATORIES: NET SALES,
    TABLE 88.DR. REDDY’S LABORATORIES: KEY STRATERGIES
    TABLE 89.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 90.ELI LILLY AND COMPANY: OPERATING SEGMENTS
    TABLE 91.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 92.ELI LILLY AND COMPANY: NET SALES,
    TABLE 93.ELI LILLY AND COMPANY: KEY STRATERGIES
    TABLE 94.INTAS PHARMACEUTICAL LTD: COMPANY SNAPSHOT
    TABLE 95.INTAS PHARMACEUTICAL LTD: OPERATING SEGMENTS
    TABLE 96.INTAS PHARMACEUTICAL LTD: PRODUCT PORTFOLIO
    TABLE 97.INTAS PHARMACEUTICAL LTD: NET SALES,
    TABLE 98.INTAS PHARMACEUTICAL LTD: KEY STRATERGIES
    TABLE 99.KASHIV BIO SCIENCES: COMPANY SNAPSHOT
    TABLE 100.KASHIV BIO SCIENCES: OPERATING SEGMENTS
    TABLE 101.KASHIV BIO SCIENCES: PRODUCT PORTFOLIO
    TABLE 102.KASHIV BIO SCIENCES: NET SALES,
    TABLE 103.KASHIV BIO SCIENCES: KEY STRATERGIES
    TABLE 104.MERCK & CO. INC.: COMPANY SNAPSHOT
    TABLE 105.MERCK & CO. INC.: OPERATING SEGMENTS
    TABLE 106.MERCK & CO. INC.: PRODUCT PORTFOLIO
    TABLE 107.MERCK & CO. INC.: NET SALES,
    TABLE 108.MERCK & CO. INC.: KEY STRATERGIES
    TABLE 109.PFIZER INC.: COMPANY SNAPSHOT
    TABLE 110.PFIZER INC.: OPERATING SEGMENTS
    TABLE 111.PFIZER INC.: PRODUCT PORTFOLIO
    TABLE 112.PFIZER INC.: NET SALES,
    TABLE 113.PFIZER INC.: KEY STRATERGIES
    TABLE 114.RELIANCE LIFE SCIENCES: COMPANY SNAPSHOT
    TABLE 115.RELIANCE LIFE SCIENCES: OPERATING SEGMENTS
    TABLE 116.RELIANCE LIFE SCIENCES: PRODUCT PORTFOLIO
    TABLE 117.RELIANCE LIFE SCIENCES: NET SALES,
    TABLE 118.RELIANCE LIFE SCIENCES: KEY STRATERGIES
    TABLE 119.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
    TABLE 120.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
    TABLE 121.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
    TABLE 122.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES,
    TABLE 123.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.BIOSIMILARS MARKET SEGMENTATION
    FIGURE 2.BIOSIMILARS MARKET,2021-2031
    FIGURE 3.BIOSIMILARS MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.BIOSIMILARS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.BIOSIMILARS MARKET,BY TYPE,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ERYTHROPOIETIN BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF MONOCLONAL ANTIBODIES BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INSULIN BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GRANULOCYTE-COLONY STIMULATING FACTOR BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 19.BIOSIMILARS MARKET,BY APPLICATION,2021(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD DISORDERS BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY DISEASES BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CHRONIC AND AUTOIMMUNE DISEASES BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS BIOSIMILARS MARKET,2021-2031(%)
    FIGURE 24.BIOSIMILARS MARKET BY REGION,2021
    FIGURE 25.U.S. BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 26.CANADA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 27.MEXICO BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 28.GERMANY BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 29.FRANCE BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 30.U.K. BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 31.ITALY BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 32.SPAIN BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 33.REST OF EUROPE BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 34.JAPAN BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 35.CHINA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 36.AUSTRALIA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 37.INDIA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 38.SOUTH KOREA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 39.REST OF ASIA-PACIFIC BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 40.BRAZIL BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 41.SAUDI ARABIA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 42.SOUTH AFRICA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 43.REST OF LAMEA BIOSIMILARS MARKET,2021-2031($MILLION)
    FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 48.COMPETITIVE DASHBOARD
    FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 50.AMGEN INC..: NET SALES ,($MILLION)
    FIGURE 51.BIOCON LTD.: NET SALES ,($MILLION)
    FIGURE 52.DR. REDDY’S LABORATORIES.: NET SALES ,($MILLION)
    FIGURE 53.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
    FIGURE 54.INTAS PHARMACEUTICAL LTD.: NET SALES ,($MILLION)
    FIGURE 55.KASHIV BIO SCIENCES.: NET SALES ,($MILLION)
    FIGURE 56.MERCK & CO. INC..: NET SALES ,($MILLION)
    FIGURE 57.PFIZER INC..: NET SALES ,($MILLION)
    FIGURE 58.RELIANCE LIFE SCIENCES.: NET SALES ,($MILLION)
    FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ,($MILLION)

 
 

This section provides opinions of top level CXOs in the biosimilars market. According to CXOs, biosimilars or biosimilar drugs have structural and therapeutic similarities with reference biologics. Biosimilars are available at lower prices as compared to biologics. 

the biosimilar market is segmented on the basis of type, application, and region. By type, it includes human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, and granulocyte-colony stimulating factor. Biosimilars are used for treatment of various diseases such as cancer, diabetes, and autoimmune diseases.

Factors such as increase in chronic diseasessuch as rise in biosimilar product approvals and development of various biosimilar drugs propel growth of the biosimilars market. In addition, increase in geriatric population and surge in demand for economical treatment of various diseases are expected to contribute toward growth of the biosimilars market.

Europe is expected to witness highest growth in terms of revenue, owing to rise in incidences of cancer, high number of biosimilars approved in the region, presence of key players for manufacturing & developing biosimilar drugs, and increase innumber of hospitals in the region.However, complexity of biosimilar development is expected to hamper the market growth

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of biosimilars market is $15,919.32 million in 2021.

A. The forecast period in the report is from 2022 to 2031.

A. Europe is the largest regional market for Biosimilars.

A. The top companies that hold the market share in biosimilars market are Amgen Inc., Biocon Ltd., Dr. Reddy’s Laboratories, Eli Lilly and Company, Intas Pharmaceutical Ltd., Kashiv Bio Sciences, Merck KGAA, Pfizer Inc., Reliance Life Sciences Private limited, and Teva Pharmaceutical Industries Ltd.

A. The market value of biosimilars market in 2022 was $19660.36 million.

A. Yes, biosimilars companies are profiled in the report

A. The key trends in the biosimilars market are increase in demand for cost effective treatment, rise in prevalence of cancer and new product approvals in the market.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Biosimilars Market

Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers